Pralnacasan, a caspase-1 blocker, has been reported to attenuate inflammation in a model of DCM by reducing IL-1β, IL-18, TNFα, and IFNγ levels, intracardiac macrophage, and lymphocyte infiltrates and also to improve insulin sensitivity [107, 111]. This evidence concerns the gene IL1B and familial dilated cardiomyopathy.